West Pharmaceutical Services (WST) Resumen de Acciones
West Pharmaceutical Services, Inc. diseña, fabrica y vende sistemas de contención y suministro para medicamentos inyectables y productos sanitarios en América, Europa, Oriente Medio, África y Asia-Pacífico. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 0/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 4/6 |
| Salud financiera | 6/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en WST a partir de nuestros controles de riesgos.
WST Community Fair Values
Create NarrativeSee what 25 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de West Pharmaceutical Services, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$319.75 |
| Máximo en las últimas 52 semanas | US$330.88 |
| Mínimo de 52 semanas | US$206.80 |
| Beta | 1.18 |
| Cambio en 1 mes | -1.89% |
| Variación en 3 meses | 36.74% |
| Cambio de 1 año | 42.89% |
| Variación en 3 años | -10.53% |
| Variación en 5 años | -7.36% |
| Variación desde la OPV | 25,009.21% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jun 06
WST: Injectable Platforms And High Value Mix Will Support Future Earnings Power
Analysts have nudged their fair value estimate for West Pharmaceutical Services higher to about $352 per share, citing refreshed price targets around $325 to $375 and continued confidence in injectable driven growth and execution. Analyst Commentary Recent Street research has focused on how West Pharmaceutical Services is executing on growth in injectables and high value product categories, and what that could mean for valuation as price targets shift higher.Seeking Alpha • Apr 30
West Pharmaceutical: Multiple Growth Drivers Are A Tailwind
Summary West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a guidance raise and share price rebound. Key growth drivers include biologics market expansion, GLP-1 drug demand, and Annex 1 regulatory upgrades, supporting recurring revenue and margin strength. I rate WST a long-term 'hold' due to exemplary dividend safety and a fortress balance sheet, but the current valuation is only slightly below fair value. Read the full article on Seeking AlphaActualización de narrativa • Apr 27
WST: Higher Margin Mix And Contract Services Expansion Will Support Earnings Power
Analysts have lifted the implied fair value estimate for West Pharmaceutical Services by about $11 to roughly $350, as a series of recent price target changes reflect updated assumptions around growth, margins and P/E multiples. Analyst Commentary Recent Street research on West Pharmaceutical Services shows a mix of upbeat and cautious messages as analysts recalibrate their models and price targets around updated assumptions for growth, margins and P/E multiples.Recent updates
Actualización de narrativa • Jun 06
WST: Injectable Platforms And High Value Mix Will Support Future Earnings Power
Analysts have nudged their fair value estimate for West Pharmaceutical Services higher to about $352 per share, citing refreshed price targets around $325 to $375 and continued confidence in injectable driven growth and execution. Analyst Commentary Recent Street research has focused on how West Pharmaceutical Services is executing on growth in injectables and high value product categories, and what that could mean for valuation as price targets shift higher.Seeking Alpha • Apr 30
West Pharmaceutical: Multiple Growth Drivers Are A Tailwind
Summary West Pharmaceutical Services maintains dominant market share in injectable drug delivery, underpinned by a wide moat and robust regulatory positioning. WST reported strong Q1 2026 results, with revenue up 21% and adjusted EPS up 46.9%, prompting a guidance raise and share price rebound. Key growth drivers include biologics market expansion, GLP-1 drug demand, and Annex 1 regulatory upgrades, supporting recurring revenue and margin strength. I rate WST a long-term 'hold' due to exemplary dividend safety and a fortress balance sheet, but the current valuation is only slightly below fair value. Read the full article on Seeking AlphaActualización de narrativa • Apr 27
WST: Higher Margin Mix And Contract Services Expansion Will Support Earnings Power
Analysts have lifted the implied fair value estimate for West Pharmaceutical Services by about $11 to roughly $350, as a series of recent price target changes reflect updated assumptions around growth, margins and P/E multiples. Analyst Commentary Recent Street research on West Pharmaceutical Services shows a mix of upbeat and cautious messages as analysts recalibrate their models and price targets around updated assumptions for growth, margins and P/E multiples.Actualización de narrativa • Feb 07
WST: Margin Resilience And Drug Delivery Portfolio Shift Will Support Earnings Power
Analysts have trimmed their price target on West Pharmaceutical Services by about US$7. This reflects updated assumptions around slightly softer revenue growth, a modestly higher discount rate, a small adjustment to future P/E expectations, and a marginally stronger profit margin outlook.Actualización de narrativa • Jan 24
WST: 2026 Drug Delivery Focus And New Syringe Platform Will Support Earnings Power
Analysts have kept their fair value estimate for West Pharmaceutical Services steady at about $345.71 per share, with only slight tweaks to assumptions like the discount rate, long term revenue growth, profit margin, and future P/E, which together feed into their updated price target narrative. What's in the News West Pharmaceutical Services agreed to sell all manufacturing and supply rights for its SmartDose 3.5 mL On Body Delivery System, along with associated facilities, to AbbVie for total consideration of US$112.5 million at close, subject to working capital and other adjustments (Key Developments).Actualización de narrativa • Jan 07
WST: Normalizing Markets And 2026 Visibility Will Support Earnings Power
Narrative update The updated analyst price target for West Pharmaceutical Services reflects a largely steady fair value near US$346. Analysts point to recent target hikes, higher EPS estimates and a constructive view on growth drivers into 2026 as key supports for the current valuation framework.Actualización de narrativa • Dec 19
WST: Normalizing End Markets Will Support Stronger Earnings Base Into 2026
Analysts have modestly raised their price target on West Pharmaceutical Services to approximately $370, up from about $310. This reflects increased earnings estimates, a stronger setup into 2026, and improving, more stable end markets.Actualización de narrativa • Dec 05
WST: Normalizing End Markets Will Support Strong Earnings Base Into 2026
Analysts have nudged their price target for West Pharmaceutical Services slightly higher to approximately $370, reflecting increased confidence in the company’s earnings power and growth drivers as market conditions normalize and set up favorably into 2026. Analyst Commentary Analyst views on West Pharmaceutical Services remain broadly constructive, with recent target hikes reflecting growing conviction that the company can sustain its earnings recovery as end markets normalize into 2026.Actualización de narrativa • Nov 21
WST: Strong 2025 Outlook and Management Confidence Will Sustain Positive Momentum
West Pharmaceutical Services has seen its average analyst price target raised, with significant increases attributed to strong quarterly results, growing end market confidence, and a positive management outlook for 2026, according to analysts. Analyst Commentary Analysts have responded to West Pharmaceutical Services' recent performance and outlook with a range of observations tying directly to the company's valuation, execution, and growth prospects.Actualización de narrativa • Nov 07
WST: Sustained Earnings Momentum Will Drive Confidence Into 2026
West Pharmaceutical Services has seen its average analyst price target rise from approximately $321 to $351. Analysts cite continued growth drivers and improved market conditions following a strong quarterly performance.Actualización de narrativa • Oct 23
Analysts Raise Target for West Pharmaceutical Services Amid Strong Outlook and Upgraded Guidance
Analysts have increased their price target for West Pharmaceutical Services by $5 to $321. They cited the company's encouraging earnings call, management's confidence in future estimates, and stable end markets with improving investment sentiment.Artículo de análisis • Jul 25
West Pharmaceutical Services, Inc.'s (NYSE:WST) Shares Climb 25% But Its Business Is Yet to Catch Up
West Pharmaceutical Services, Inc. ( NYSE:WST ) shareholders have had their patience rewarded with a 25% share price...Artículo de análisis • Jul 13
Here's Why West Pharmaceutical Services (NYSE:WST) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Seeking Alpha • Mar 11
West Pharmaceutical: Remains A Strong Long-Term Prospect
Summary West Pharmaceutical Services has faced a challenging year, underperforming against the index, with declining volumes, margins, and returns, but remains a strong long-term investment. The company's high-value products segment, driven by GLP-1 medications and biologics, is expected to boost margins and returns significantly. Despite poor timing in share buybacks and management concerns, West's valuation suggests a potential 12.8% annual return, making it a buy. Key risks include management's strategic decisions and valuation, but the worst seems behind, with attractive prices for long-term growth. Read the full article on Seeking AlphaSeeking Alpha • Feb 17
West Pharmaceuticals Takes A Plunge, But May Still Offer Opportunities
Summary The price of West Pharmaceutical Services plunged over 38% after it released its Q4 and FY 2024 earnings results on February 13. Shareholders, mostly institutional investors apparently, did not like the bottom-line results nor the uninspiring guidance for 2025. Still, West should not be overlooked, and there may be opportunities if the share price continues to rebound after a market overreaction. Read the full article on Seeking AlphaSeeking Alpha • Jan 08
West Pharmaceuticals: Cannot Wrap My Head Around Valuations (Rating Downgrade)
Summary West Pharmaceutical Services stock is down 16% on deteriorating fundamentals. WST's business is contracting, with lower sales growth, compressed margins, and declining ROIC, making current valuations unjustifiable. Industry advantages exist, but high multiples and low incremental returns suggest limited compounding ability. I revise WST to hold with a $300-$330/share valuation, emphasizing the need for it to produce 4%+ sales growth and improved ROIC FY'26 to justify current prices. Read the full article on Seeking AlphaSeeking Alpha • Oct 11
West Pharma's Destocking Dilemma: Why Staying On The Sidelines Makes Sense
Summary West Pharmaceutical Services' stock has been sluggish, trading near its 52-week low, with analysts downgrading estimates and technical indicators pointing to further downside. The company has a strong market position in injectable drug delivery systems, but post-COVID demand normalization and destocking have impacted recent performance. Despite robust seasonal trends, the stock is vulnerable to tax-loss selling, with Morgan Stanley naming it among the most at-risk stocks. Given these factors, a cautious hold on West Pharma is recommended, awaiting potential recovery in Q4 and beyond. Read the full article on Seeking AlphaRentabilidad de los accionistas
| WST | US Life Sciences | Mercado US | |
|---|---|---|---|
| 7D | 1.1% | -1.4% | -2.5% |
| 1Y | 42.9% | 10.1% | 22.7% |
Rentabilidad vs. Industria: WST superó a la industria US Life Sciences, que obtuvo un rendimiento del 10.1% el año pasado.
Rentabilidad vs. Mercado: WST superó al mercado US, que obtuvo un rendimiento del 22.7% el año pasado.
Volatilidad de los precios
| WST volatility | |
|---|---|
| WST Average Weekly Movement | 5.3% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: WST no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de WST (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1923 | 10,800 | Eric Green | www.westpharma.com |
West Pharmaceutical Services, Inc. diseña, fabrica y vende sistemas de contención y suministro para medicamentos inyectables y productos sanitarios en América, Europa, Oriente Medio, África y Asia-Pacífico. Opera en dos segmentos: Productos patentados y Productos fabricados por contrato. El segmento de productos patentados ofrece tapones y sellos para sistemas de envasado de inyectables; componentes para jeringuillas y cartuchos, incluidas soluciones personalizadas para las necesidades de las aplicaciones de medicamentos inyectables, así como sistemas de administración que mejoran la administración segura de fármacos mediante tecnologías avanzadas de reconstitución, mezcla y transferencia; y películas, revestimientos, procesos y servicios de lavado, inspección visual y esterilización para mejorar la calidad de los productos de envasado.
Resumen de fundamentos de West Pharmaceutical Services, Inc.
| Estadísticas fundamentales de WST | |
|---|---|
| Capitalización bursátil | US$22.22b |
| Beneficios(TTM) | US$542.70m |
| Ingresos (TTM) | US$3.22b |
41.6x
Ratio precio-beneficio (PE)7.0x
Ratio precio-ventas (PS)¿Está WST sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de WST | |
|---|---|
| Ingresos | US$3.22b |
| Coste de los ingresos | US$2.05b |
| Beneficio bruto | US$1.17b |
| Otros gastos | US$625.80m |
| Beneficios | US$542.70m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 7.68 |
| Margen bruto | 36.28% |
| Margen de beneficio neto | 16.85% |
| Ratio deuda/patrimonio | 6.8% |
¿Cómo se ha desempeñado WST a largo plazo?
Ver rendimiento histórico y comparativaDividendos
0.3%
Rentabilidad actual por dividendo11%
Ratio de pagosAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/06/08 23:46 |
| Precio de las acciones al final del día | 2026/06/08 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
West Pharmaceutical Services, Inc. está cubierta por 26 analistas. 14 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Lawrence Marsh | Barclays |
| Luke Sergott | Barclays |
| Michael Ryskin | BofA Global Research |